These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 23807596

  • 21. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J, Pachinger C, Pelz M, Kleiser R.
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [Abstract] [Full Text] [Related]

  • 22. Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis.
    Kording F, Weidensteiner C, Zwick S, Osterberg N, Weyerbrock A, Staszewski O, von Elverfeldt D, Reichardt W.
    J Magn Reson Imaging; 2014 Dec; 40(6):1310-8. PubMed ID: 24390982
    [Abstract] [Full Text] [Related]

  • 23. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
    Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Papadatos-Pastos D, Brunetto A, Tunariu N, Mann H, Tessier J, Young H, Ghiorghiu D, Marley S, Kaye SB, deBono JS, Leach MO, deSouza NM.
    Radiology; 2012 Nov; 265(2):426-36. PubMed ID: 22891356
    [Abstract] [Full Text] [Related]

  • 24. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT, Shih TT, Chen RC, Tu SY, Hsieh WY, Yang PC.
    Mol Imaging; 2012 Nov; 11(4):286-300. PubMed ID: 22954145
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cluster analysis of DCE-MRI data identifies regional tracer-kinetic changes after tumor treatment with high intensity focused ultrasound.
    Jacobs I, Hectors SJ, Schabel MC, Grüll H, Strijkers GJ, Nicolay K.
    NMR Biomed; 2015 Nov; 28(11):1443-54. PubMed ID: 26390040
    [Abstract] [Full Text] [Related]

  • 27. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
    Gaustad JV, Simonsen TG, Smistad R, Wegner CS, Andersen LM, Rofstad EK.
    BMC Cancer; 2015 Nov 14; 15():900. PubMed ID: 26573613
    [Abstract] [Full Text] [Related]

  • 28. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
    Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV.
    AJR Am J Roentgenol; 2015 Jan 14; 204(1):W11-8. PubMed ID: 25539263
    [Abstract] [Full Text] [Related]

  • 29. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
    Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ.
    Neoplasia; 2005 May 14; 7(5):475-85. PubMed ID: 15967100
    [Abstract] [Full Text] [Related]

  • 30. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
    Veeravagu A, Hou LC, Hsu AR, Cai W, Greve JM, Chen X, Tse V.
    Neurol Res; 2008 Nov 14; 30(9):952-9. PubMed ID: 18662497
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P, White NS, Farid N, Chung R, Kuperman JM, Girard HM, Shankaranarayanan A, Kesari S, McDonald CR, Dale AM.
    AJNR Am J Neuroradiol; 2013 Sep 14; 34(9):1752-1757. PubMed ID: 23578667
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.
    Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA.
    Gynecol Oncol; 2012 Sep 14; 126(3):375-80. PubMed ID: 22683587
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.